Leerink Partners analyst Mike Kratky reiterated a Buy rating on AxoGen (AXGN – Research Report) on March 31 and set a price target of $25.00.
Mike Kratky has given his Buy rating due to a combination of factors including the anticipation of a more typical revenue seasonality pattern for AxoGen through 2025 and the positive investment outlook. The adjustments made to the revenue estimates for the first quarter of 2025 account for expected seasonal variations, with a more significant growth anticipated in the latter half of the year.
Additionally, the recent updates in the company’s shares outstanding, as reflected in their latest 10K filing, do not materially alter the long-term estimates or investment thesis. The upcoming expected approval of Avance BLA, with a PDUFA date set for September 5th, 2025, further strengthens the positive outlook for AxoGen. Overall, these factors contribute to an attractive investment setup for the company over the next year and beyond.
In another report released on March 18, Cantor Fitzgerald also maintained a Buy rating on the stock with a $24.00 price target.
AXGN’s price has also changed moderately for the past six months – from $14.020 to $18.500, which is a 31.95% increase.